In addition, the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) and GETUG-AFU 12 studies have assessed chemotherapy plus ADT for non-metastatic patients with a high-risk of localized disease (e.g. elevated prostate specific antigen − PSA at diagnosis and high-grade tumors). This evidence concerns the gene KLK3 and prostate carcinoma.